Form 8-K Teladoc Health, Inc. For: Jul 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Teladoc (TDOC) PT Lowered to $8 at Jefferies
August 2, 2024 3:28 PM EDTJefferies analyst Glen Santangelo lowered the price target on Teladoc (NYSE: TDOC) to $8.00 (from $10.00) while maintaining a Hold rating.
The analyst comments "We are updating our model to account for 2Q earnings and updated management commentary. We are lowering our estimates to... More
Teladoc (TDOC) PT Lowered to $10 at Deutsche Bank
August 1, 2024 4:00 PM EDTDeutsche Bank analyst George Hill lowered the price target on Teladoc (NYSE: TDOC) to $10.00 (from $15.00) while maintaining a Hold rating.
The analyst comments "TDOC Provides Half-a-Guidance as BetterHelp Struggles: TDOC reported Q2 results where the company pulled its 2024 and long term... More
Teladoc (TDOC) PT Lowered to $9 at RBC Capital
August 1, 2024 6:32 AM EDTRBC Capital analyst Sean Dodge lowered the price target on Teladoc (NYSE: TDOC) to $9.00 (from $18.00) while maintaining a Outperform rating.
The analyst comments "Q2 was challenging for TDOC. Revenue missed consensus by 1.1% and while EBITDA came in 20.4% ahead, much of the upside was... More

